Comparative Pharmacology
Head-to-head clinical analysis: LARIN FE 1 20 versus LOARGYS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LARIN FE 1 20 versus LOARGYS.
LARIN FE 1/20 vs LOARGYS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LARIN FE 1/20 is a combination oral contraceptive containing ethinyl estradiol and norethindrone. It inhibits ovulation by suppressing gonadotropin release (FSH and LH) from the pituitary, increases viscosity of cervical mucus, and alters endometrial receptivity.
LOARGYS is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever.
One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo (ferrous fumarate) tablets per cycle.
100 mg orally twice daily.
None Documented
None Documented
Ethinyl estradiol: ~13 hours (range 7-20); norethindrone: ~8-11 hours. Steady-state reached in 5-7 days.
Terminal elimination half-life: 12-18 hours (prolonged in renal impairment).
Renal (60% as metabolites, <10% unchanged); biliary/fecal (40%)
Primarily renal (70-80% unchanged; 10-15% as metabolites); biliary/fecal (5-10%).
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive